Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 520 IDR -0.95% Market Closed
Market Cap: 5.8T IDR

EV/EBIT
Enterprise Value to EBIT

-77.4
Current
-38.6
Median
16.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-77.4
=
Enterprise Value
9.9T IDR
/
EBIT
-128.2B IDR
EBIT Growth EV/EBIT to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBIT: 1 878.2
Negative Multiple: -77.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.1
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.3
14%
1.4
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
170.1
22%
7.7
CH
Novartis AG
SIX:NOVN
13.6
12%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
6%
1.7
US
Merck & Co Inc
NYSE:MRK
9.8
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A